• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Eclipsing Toxicity, Enhancing Efficacy: Clofazimine's Vanguard in the Realm of Anti-PD-1 and CTLA-4 Immunotherapy.

作者信息

Tan Ruirong, Zhao Junning, Shubhra Quazi T H

机构信息

Translational Chinese Medicine Key Laboratory of Sichuan Province, Sichuan Institute for Translational Chinese Medicine, Sichuan Academy of Chinese Medicine Sciences, Chengdu 610041, China.

National Medical Products Administration (NMPA), Beijing 100038, China.

出版信息

Research (Wash D C). 2024 Jul 9;7:0419. doi: 10.34133/research.0419. eCollection 2024.

DOI:10.34133/research.0419
PMID:39156659
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11328404/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a368/11328404/ce8f3a65565a/research.0419.fig.001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a368/11328404/ce8f3a65565a/research.0419.fig.001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a368/11328404/ce8f3a65565a/research.0419.fig.001.jpg

相似文献

1
Eclipsing Toxicity, Enhancing Efficacy: Clofazimine's Vanguard in the Realm of Anti-PD-1 and CTLA-4 Immunotherapy.超越毒性，增强疗效：氯法齐明在抗PD-1和CTLA-4免疫治疗领域的先锋作用
Research (Wash D C). 2024 Jul 9;7:0419. doi: 10.34133/research.0419. eCollection 2024.
2
Dual blockade immunotherapy targeting PD-1/PD-L1 and CTLA-4 in lung cancer.肺癌中 PD-1/PD-L1 和 CTLA-4 的双重阻断免疫疗法。
J Hematol Oncol. 2024 Jul 27;17(1):54. doi: 10.1186/s13045-024-01581-2.
3
Efficacy comparison between anti-PD-1 antibody monotherapy and anti-PD-1 plus anti-CTLA-4 combination therapy as first-line immunotherapy for advanced acral melanoma: A retrospective, multicenter study of 254 Japanese patients.抗 PD-1 抗体单药治疗与抗 PD-1 联合抗 CTLA-4 联合治疗作为一线免疫治疗晚期肢端黑色素瘤的疗效比较：254 例日本患者的回顾性多中心研究。
Eur J Cancer. 2022 Nov;176:78-87. doi: 10.1016/j.ejca.2022.08.030. Epub 2022 Oct 1.
4
Mechanisms and microbial influences on CTLA-4 and PD-1-based immunotherapy in the treatment of cancer: a narrative review.癌症治疗中基于CTLA-4和PD-1免疫疗法的机制及微生物影响：一项叙述性综述
Gut Pathog. 2020 Sep 10;12:43. doi: 10.1186/s13099-020-00381-6. eCollection 2020.
5
Clinical drug screening reveals clofazimine potentiates the efficacy while reducing the toxicity of anti-PD-1 and CTLA-4 immunotherapy.临床药物筛选显示氯法齐明增强了抗 PD-1 和 CTLA-4 免疫疗法的疗效，同时降低了其毒性。
Cancer Cell. 2024 May 13;42(5):780-796.e6. doi: 10.1016/j.ccell.2024.03.001. Epub 2024 Mar 21.
6
Combining anti-cytotoxic T-lymphocyte antigen 4 (CTLA-4) and -programmed cell death protein 1 (PD-1) agents for cancer immunotherapy.联合抗细胞毒性 T 淋巴细胞相关抗原 4（CTLA-4）和程序性细胞死亡蛋白 1（PD-1）药物进行癌症免疫治疗。
Expert Opin Biol Ther. 2021 Dec;21(12):1623-1634. doi: 10.1080/14712598.2021.1921140. Epub 2021 May 4.
7
Clofazimine for the treatment of tuberculosis.氯法齐明用于治疗结核病。
Front Pharmacol. 2023 Feb 2;14:1100488. doi: 10.3389/fphar.2023.1100488. eCollection 2023.
8
Targeting immunosuppressive Ly6C+ classical monocytes reverses anti-PD-1/CTLA-4 immunotherapy resistance.靶向抑制性 Ly6C+经典单核细胞可逆转抗 PD-1/CTLA-4 免疫治疗耐药性。
Front Immunol. 2023 Jun 28;14:1161869. doi: 10.3389/fimmu.2023.1161869. eCollection 2023.
9
Targeting interferon signaling and CTLA-4 enhance the therapeutic efficacy of anti-PD-1 immunotherapy in preclinical model of HPV oral cancer.针对干扰素信号和 CTLA-4 可增强 HPV 口腔癌临床前模型中抗 PD-1 免疫治疗的疗效。
J Immunother Cancer. 2019 Sep 18;7(1):252. doi: 10.1186/s40425-019-0728-4.
10
Characterization of liver injury induced by cancer immunotherapy using immune checkpoint inhibitors.使用免疫检查点抑制剂的癌症免疫疗法诱导的肝损伤的特征。
J Hepatol. 2018 Jun;68(6):1181-1190. doi: 10.1016/j.jhep.2018.01.033. Epub 2018 Feb 8.

引用本文的文献

1
Daurisoline Modulates the TBK1-Dependent Type I Interferon Pathway to Boost Anti-tumor Immunity via Targeting of LRP1.蝙蝠葛碱通过靶向低密度脂蛋白受体相关蛋白1（LRP1）调节TBK1依赖的I型干扰素途径以增强抗肿瘤免疫。
Research (Wash D C). 2025 Jul 4;8:0764. doi: 10.34133/research.0764. eCollection 2025.

本文引用的文献

1
Beyond the danger signal: RNA aggregates orchestrate immunotherapy.超越危险信号：RNA 聚集物调控免疫疗法。
Trends Mol Med. 2024 Aug;30(8):702-704. doi: 10.1016/j.molmed.2024.05.018. Epub 2024 Jun 11.
2
Targeting metabolic circuitry to supercharge CD8 T cell antitumor responses.靶向代谢通路以增强 CD8 T 细胞抗肿瘤反应。
Cell Metab. 2024 May 7;36(5):884-886. doi: 10.1016/j.cmet.2024.04.007.
3
Clinical drug screening reveals clofazimine potentiates the efficacy while reducing the toxicity of anti-PD-1 and CTLA-4 immunotherapy.
临床药物筛选显示氯法齐明增强了抗 PD-1 和 CTLA-4 免疫疗法的疗效，同时降低了其毒性。
Cancer Cell. 2024 May 13;42(5):780-796.e6. doi: 10.1016/j.ccell.2024.03.001. Epub 2024 Mar 21.
4
Supramolecular Biomaterials for Cancer Immunotherapy.用于癌症免疫治疗的超分子生物材料。
Research (Wash D C). 2023 Sep 12;6:0211. doi: 10.34133/research.0211. eCollection 2023.
5
Emerging Nano-/Biotechnology Drives Oncolytic Virus-Activated and Combined Cancer Immunotherapy.新兴的纳米/生物技术推动溶瘤病毒激活及联合癌症免疫治疗。
Research (Wash D C). 2023;6:0108. doi: 10.34133/research.0108. Epub 2023 Apr 3.
6
Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer.纳武利尤单抗联合伊匹单抗治疗晚期非小细胞肺癌。
N Engl J Med. 2019 Nov 21;381(21):2020-2031. doi: 10.1056/NEJMoa1910231. Epub 2019 Sep 28.
7
Selective inhibition of low-affinity memory CD8 T cells by corticosteroids.糖皮质激素选择性抑制低亲和力记忆 CD8 T 细胞。
J Exp Med. 2019 Dec 2;216(12):2701-2713. doi: 10.1084/jem.20190738. Epub 2019 Sep 19.
8
Combined immune checkpoint blockade (anti-PD-1/anti-CTLA-4): Evaluation and management of adverse drug reactions.联合免疫检查点阻断（抗 PD-1/抗 CTLA-4）：药物不良反应的评估和管理。
Cancer Treat Rev. 2017 Jun;57:36-49. doi: 10.1016/j.ctrv.2017.05.003. Epub 2017 May 18.